Table 2.
Selected novel target clinical trials for NEPC.
| Trial Identifier | Status | Phase | Drug/Treatment | Target | Additional Drugs | NEPC Exclusive Cohorts |
|---|---|---|---|---|---|---|
| NCT02709889 | Terminated | 1 | Rovalpituzumab tesirine (SC16LD6.5) | DLL3 | Yes | |
| NCT05652686 | Recruiting | 1 | PT217 | DLL3 | Yes | |
| NCT04702737 | Active, not recruiting |
1 | AMG 757 | DLL3 | Yes | |
| NCT03480646 | Unknown status |
1/2 | CPI-1205 | EZH2 | Enzalutamide, Abiraterone/ Prednisone |
Yes |
| NCT02875548 | Active, not recruiting |
1/2 | Tazemetostat | EZH2 | No | |
| NCT02381314 | Completed | 1 | Enoblituzumab (MGA271) | B7-H3 | Ipilimumab | No |
| NCT05293496 | Recruiting | 1/2 | Vobramitamab Duocarmazine (MGC018) | B7-H3 | Lorigerlimab | No |
| NCT01094288 | Completed | 1 | Alisertib (MLN8237) | Aurora-A | Docetaxel | No |
| NCT01799278 | Completed | 2 | Alisertib (MLN8237) | Aurora-A | Yes | |
| NCT03179410 | Completed | 2 | Avelumab | PD-L1 | Yes | |
| NCT03365791 | Completed | 2 | PDR001 | PD-1 | Lag525 | No |
| NCT04926181 | Active, not recruiting | 2 | Cetrelimab (JNJ-63723283) | PD-1 | Apalutamide | Yes |
| NCT04592237 | Recruiting | 2 | Cetrelimab (JNJ-63723283) | PD-1 | Cabazitaxel, carboplatin, followed by nirparib | Yes |
| NCT03866382 | Recruiting | 2 | Cabozantinib | Receptor Tyrosine Kinases | Yes | |
| COMET-1, -2 | Completed | 3 | Cabozantinib | Receptor Tyrosine Kinases | No |